A randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of Nexvax2 in patients with celiac disease.

Trial Profile

A randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of Nexvax2 in patients with celiac disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs HLA DQ2 peptide vaccine (Primary)
  • Indications Coeliac disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ImmusanT
  • Most Recent Events

    • 12 May 2017 Results from this and other trial (see profile 215705) published in an ImmusanT Media Release
    • 11 May 2017 Status changed from active, no longer recruiting to completed, as reported in an article published in The Lancet Gastroenterology and Hepatology
    • 11 May 2017 Results from this and other trial (see profile 215705) published in The Lancet Gastroenterology and Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top